MASLD DEVELOPMENT: FROM MOLECULAR PATHOGENESIS TOWARD THERAPEUTIC STRATEGIES

Descargar Publicación
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Tria Dosis baja de semaglutida mejora la insuficiencia cardíaca con mínima pérdida de peso